Skip to main content

Multiple Sclerosis: Ad Scientiam begins an innovative clinical trial program

Ad Scientiam launches its own validation clinical study on 200 patients in 10 Neurology centers specialized in Multiple Sclerosis

Ad Scientiam mobilizes its resources on an innovative digital research project, in the Neurology field: "DAMS, Digital Assessment in Multiple Sclerosis".

This project gathers teams from 10 French hospitals specialized in Neurology (and particularly in MS).

The main objective of this study is to demonstrate the validity and the strength of a new composite score to evaluate MS through exercises taken on a smartphone.

 

 

The first step is to evaluate the benefits of the DAMS mobile medical application on 200 patients with MS.

This multi-centric study is the first milestone of this program, which aims at providing new innovative assessment scales for chronic diseases.

« Ad Scientiam is dedicated to the development of innovative applications for the monitoring and the assessment of patients in real life. Being located within the Brain and Spine Institute, at the center of the largest Research Hospital in Europe, makes it easier to collaborate with the main research teams in France. DAMS is a real opportunity to identify new monitoring parameters for patients" explains Severine Bieuvelet, Head of Clinical Research at Ad Scientiam.

 

Multiple Sclerosis concerns around 70,000 and 90,000 patients in France today, with a probable annual incidence rate of 4 to 6 for 100,000 inhabitants. It is a major chronic disease, evolving usually in a progressive but unpredictable way. It affects the myelin in the central nervous system, through a mechanism still unknown.

It usually starts with patients around 30 years old (20-40), with a feminine preponderance (sex ratio of 1.7/1). MS is the first non-traumatic cause for acquired severe handicap in young people. The provoked disabilities and handicaps can have a major impact on patients' family and work life.*

 

* HAS Sclérose en plaques, Guide affection de longue durée, 2006

Latest News

Ad Scientiam launches its own validation clinical study on 200 patients in 10 Neurology centers specialized in Multiple Sclerosis

An article about Ad Scientiam and how new information and communication technologies impact healthcare. In French

Despite the innovation that could bring ResearchKit to clinical research, its use in France is currently limited. Indeed, legislation about clinical...

Ad Scientiam collaborates with researchers to improve our understanding about Attention Deficit Disorder with or without Hyperactivity.

Ad Scientiam collaborates with Dr. Mehran Firouzeh in a draft CEBT

Ad scientiam teams up with young researchers by supporting them during their study and by allowing them to have an access to its application.

Last april, Apple just launched a new promising tool for medical research : ResearchKit. This software is an open source framework which include...

The BRAiN’US project was born at the Brain and Spine Institute. The goal of the project is to gather information on how the brain really works.

Symptoms and side effects can be collected in real time from patients through their smartphone.

Asthma

Ad Scientiam Research allows collecting data relative to asthma symptoms as often as required using the notification tool.

Parasomnia

Ad Scientiam also contributes to sleep research by allowing data gathering in order to better understand our sleeping patterns.

Inclusion in cohorts

Ad Scientiam Research allows exploring small changes in environments and patient symptoms.

Nutrition

Ad Scientiam constructs tools for epidemiological studies regarding exercises / physical activities performed by obese patients.

Ad Scientiam is also concerned by the health of younger patients and has set as one of its objectives to promote sport and balanced diet.

In collaboration with a cardiology department and an engineering school, Ad Scientiam is developing an electronic aftercare telemonitoring solution...

Alcohol dependency

Patients can type in data concerning their alcohol usage and benefit from personalised help and follow up on their progress.

Patient compliance

Ad Scientiam is developing a solution allowing increasing patient answering rate as it coaches patients to improve answer rates to questions.

Parkinson's disease

Ad Scientiam contributes to research by gathering and analyzing data on Parkinson's symptom changes.

Addiction medicine

Understand and quantify the cannabis use on patient is an important step for addiction specialists.

Understanding Real World Data history